董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Matthew Angel | 男 | Chief Executive Officer and Director and President | 46 | 未披露 | 506.86 | 2026-05-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Matthew Angel | 男 | Chief Executive Officer and Director and President | 46 | 未披露 | 506.86 | 2026-05-23 |
| Nicholas Maestas | 男 | Chief Financial Officer and Corporate Secretary and Head of Corporate Strategy | 46 | 111.03万美元 | 3.69 | 2026-05-23 |
| Justin Trojanowski | 男 | Corporate Controller and Principal Accounting Officer | -- | 未披露 | 未持股 | 2026-05-23 |
董事简历
中英对照 | 中文 | 英文- Matthew Angel
-
Matthew Angel博士自2023年1月1日起担任首席执行官，自2022年5月起担任临时总裁、首席执行官和Eterna Therapeutics Inc.董事之一。在此之前，安吉尔博士是因子生物科学的联合创始人，自2011年起担任该公司总裁、首席执行官和董事会主席。2020年，安吉尔博士与他人共同创立了Exacis，并担任该公司的科学顾问委员会主席。安吉尔博士曾在2014年至2021年7月Novellus出售给Eterna Therapeutics Inc.之前担任Exacis的首席科学官、秘书、财务主管和董事，以及Novellus的首席科学官、秘书和董事。Angel博士于2012年获得麻省理工学院博士学位，2003年获得普林斯顿大学工程学学士学位。Angel博士在Eterna Therapeutics Inc.董事会任职的资格包括他在医疗保健行业的专业知识、他的商业培训和教育，以及他管理生物技术公司的丰富经验。
Matthew Angel,Ph.D., has served as Chief Executive Officer since January 1, 2023 and as Interim President, Chief Executive Officer and one of Eterna Therapeutics Inc. directors since May 2022. Prior to that, Dr. Angel co-founded Factor Bioscience, and has served as its President, Chief Executive Officer and Chairman of its Board of Directors from since 2011. In 2020, Dr. Angel co-founded Exacis, for which he serves as the Scientific Advisory Board Chair. Dr. Angel previously served as the Chief Science Officer, Secretary, Treasurer and as a director of Exacis and as the Chief Science Officer, Secretary and as a director of Novellus from 2014 until the sale of Novellus to Eterna Therapeutics Inc. in July 2021. Dr. Angel received a Ph.D. from the Massachusetts Institute of Technology in 2012 and a B.S. in Engineering from Princeton University in 2003. - Matthew Angel博士自2023年1月1日起担任首席执行官，自2022年5月起担任临时总裁、首席执行官和Eterna Therapeutics Inc.董事之一。在此之前，安吉尔博士是因子生物科学的联合创始人，自2011年起担任该公司总裁、首席执行官和董事会主席。2020年，安吉尔博士与他人共同创立了Exacis，并担任该公司的科学顾问委员会主席。安吉尔博士曾在2014年至2021年7月Novellus出售给Eterna Therapeutics Inc.之前担任Exacis的首席科学官、秘书、财务主管和董事，以及Novellus的首席科学官、秘书和董事。Angel博士于2012年获得麻省理工学院博士学位，2003年获得普林斯顿大学工程学学士学位。Angel博士在Eterna Therapeutics Inc.董事会任职的资格包括他在医疗保健行业的专业知识、他的商业培训和教育，以及他管理生物技术公司的丰富经验。
- Matthew Angel,Ph.D., has served as Chief Executive Officer since January 1, 2023 and as Interim President, Chief Executive Officer and one of Eterna Therapeutics Inc. directors since May 2022. Prior to that, Dr. Angel co-founded Factor Bioscience, and has served as its President, Chief Executive Officer and Chairman of its Board of Directors from since 2011. In 2020, Dr. Angel co-founded Exacis, for which he serves as the Scientific Advisory Board Chair. Dr. Angel previously served as the Chief Science Officer, Secretary, Treasurer and as a director of Exacis and as the Chief Science Officer, Secretary and as a director of Novellus from 2014 until the sale of Novellus to Eterna Therapeutics Inc. in July 2021. Dr. Angel received a Ph.D. from the Massachusetts Institute of Technology in 2012 and a B.S. in Engineering from Princeton University in 2003.
高管简历
中英对照 | 中文 | 英文- Matthew Angel
Matthew Angel博士自2023年1月1日起担任首席执行官，自2022年5月起担任临时总裁、首席执行官和Eterna Therapeutics Inc.董事之一。在此之前，安吉尔博士是因子生物科学的联合创始人，自2011年起担任该公司总裁、首席执行官和董事会主席。2020年，安吉尔博士与他人共同创立了Exacis，并担任该公司的科学顾问委员会主席。安吉尔博士曾在2014年至2021年7月Novellus出售给Eterna Therapeutics Inc.之前担任Exacis的首席科学官、秘书、财务主管和董事，以及Novellus的首席科学官、秘书和董事。Angel博士于2012年获得麻省理工学院博士学位，2003年获得普林斯顿大学工程学学士学位。Angel博士在Eterna Therapeutics Inc.董事会任职的资格包括他在医疗保健行业的专业知识、他的商业培训和教育，以及他管理生物技术公司的丰富经验。
Matthew Angel,Ph.D., has served as Chief Executive Officer since January 1, 2023 and as Interim President, Chief Executive Officer and one of Eterna Therapeutics Inc. directors since May 2022. Prior to that, Dr. Angel co-founded Factor Bioscience, and has served as its President, Chief Executive Officer and Chairman of its Board of Directors from since 2011. In 2020, Dr. Angel co-founded Exacis, for which he serves as the Scientific Advisory Board Chair. Dr. Angel previously served as the Chief Science Officer, Secretary, Treasurer and as a director of Exacis and as the Chief Science Officer, Secretary and as a director of Novellus from 2014 until the sale of Novellus to Eterna Therapeutics Inc. in July 2021. Dr. Angel received a Ph.D. from the Massachusetts Institute of Technology in 2012 and a B.S. in Engineering from Princeton University in 2003.- Matthew Angel博士自2023年1月1日起担任首席执行官，自2022年5月起担任临时总裁、首席执行官和Eterna Therapeutics Inc.董事之一。在此之前，安吉尔博士是因子生物科学的联合创始人，自2011年起担任该公司总裁、首席执行官和董事会主席。2020年，安吉尔博士与他人共同创立了Exacis，并担任该公司的科学顾问委员会主席。安吉尔博士曾在2014年至2021年7月Novellus出售给Eterna Therapeutics Inc.之前担任Exacis的首席科学官、秘书、财务主管和董事，以及Novellus的首席科学官、秘书和董事。Angel博士于2012年获得麻省理工学院博士学位，2003年获得普林斯顿大学工程学学士学位。Angel博士在Eterna Therapeutics Inc.董事会任职的资格包括他在医疗保健行业的专业知识、他的商业培训和教育，以及他管理生物技术公司的丰富经验。
- Matthew Angel,Ph.D., has served as Chief Executive Officer since January 1, 2023 and as Interim President, Chief Executive Officer and one of Eterna Therapeutics Inc. directors since May 2022. Prior to that, Dr. Angel co-founded Factor Bioscience, and has served as its President, Chief Executive Officer and Chairman of its Board of Directors from since 2011. In 2020, Dr. Angel co-founded Exacis, for which he serves as the Scientific Advisory Board Chair. Dr. Angel previously served as the Chief Science Officer, Secretary, Treasurer and as a director of Exacis and as the Chief Science Officer, Secretary and as a director of Novellus from 2014 until the sale of Novellus to Eterna Therapeutics Inc. in July 2021. Dr. Angel received a Ph.D. from the Massachusetts Institute of Technology in 2012 and a B.S. in Engineering from Princeton University in 2003.
- Nicholas Maestas
Nicholas Maestas，自2021年7月起担任Tempest Therapeutics Inc战略和财务副总裁，自2022年9月起担任Tempest Therapeutics Inc公司秘书。在加入Tempest Therapeutics Inc之前，Maestas先生于2019年7月至2021年7月在开发治疗神经退行性疾病的疗法的生物制药公司Alector担任FP & A和战略财务主管。在加入Alector之前，2014年11月至2019年7月，Maestas先生曾在Immune Design（一家肿瘤免疫治疗公司，于2019年被默沙东 & Co收购）担任多种职务，包括2019年1月至7月担任企业发展与运营高级总监，2017年1月至2018年12月担任企业发展与运营总监。Maestas先生获得了加州大学伯克利分校的分子和细胞生物学学士学位，以及宾夕法尼亚大学沃顿商学院的工商管理硕士学位。
Nicholas Maestas has served as Tempest Therapeutics Inc's Chief Financial Officer and Head of Corporate Strategy since January 2025, having previously served as Vice President, Finance and Strategy from July 2021 through December 2024, and has served as Tempest Therapeutics Inc's Corporate Secretary since September 2022. Prior to joining Tempest Therapeutics Inc, Mr. Maestas served as the head of FP&A and strategic finance at Alector, a biopharmaceutical company that develops therapies for the treatment of neurodegeneration diseases, from July 2019 to July 2021. Prior to joining Alector, from November 2014 to July 2019, Mr. Maestas served in a variety of roles at Immune Design, an oncology immunotherapy company that was acquired by Merck in 2019, including as Senior Director, Corporate Development & Operations from January to July 2019 and Director, Corporate Development & Operations from January 2017 to December 2018. Mr. Maestas received a B.A. in Molecular and Cell Biology from the University of California, Berkeley and an M.B.A. from The Wharton School, University of Pennsylvania.- Nicholas Maestas，自2021年7月起担任Tempest Therapeutics Inc战略和财务副总裁，自2022年9月起担任Tempest Therapeutics Inc公司秘书。在加入Tempest Therapeutics Inc之前，Maestas先生于2019年7月至2021年7月在开发治疗神经退行性疾病的疗法的生物制药公司Alector担任FP & A和战略财务主管。在加入Alector之前，2014年11月至2019年7月，Maestas先生曾在Immune Design（一家肿瘤免疫治疗公司，于2019年被默沙东 & Co收购）担任多种职务，包括2019年1月至7月担任企业发展与运营高级总监，2017年1月至2018年12月担任企业发展与运营总监。Maestas先生获得了加州大学伯克利分校的分子和细胞生物学学士学位，以及宾夕法尼亚大学沃顿商学院的工商管理硕士学位。
- Nicholas Maestas has served as Tempest Therapeutics Inc's Chief Financial Officer and Head of Corporate Strategy since January 2025, having previously served as Vice President, Finance and Strategy from July 2021 through December 2024, and has served as Tempest Therapeutics Inc's Corporate Secretary since September 2022. Prior to joining Tempest Therapeutics Inc, Mr. Maestas served as the head of FP&A and strategic finance at Alector, a biopharmaceutical company that develops therapies for the treatment of neurodegeneration diseases, from July 2019 to July 2021. Prior to joining Alector, from November 2014 to July 2019, Mr. Maestas served in a variety of roles at Immune Design, an oncology immunotherapy company that was acquired by Merck in 2019, including as Senior Director, Corporate Development & Operations from January to July 2019 and Director, Corporate Development & Operations from January 2017 to December 2018. Mr. Maestas received a B.A. in Molecular and Cell Biology from the University of California, Berkeley and an M.B.A. from The Wharton School, University of Pennsylvania.
- Justin Trojanowski
Justin Trojanowski自2022年9月起担任公司公司财务总监、财务主管和首席会计官。此前，Trojanowski先生于2022年6月至2022年9月期间担任董事、财务和助理财务总监。在加入公司之前，Trojanowski先生于2019年6月至2022年6月期间在生物制药公司内克塔治疗担任副董事，会计部。在加入Nektar之前，Trojanowski先生曾于2018年6月至2019年5月担任高级经理，在Immune Design担任会计，该公司是一家晚期肿瘤公司，于2019年被默沙东收购。在加入Immune Design之前，Trojanowski先生于2012年9月至2018年5月在跨国审计和专业服务公司Ernst & Young，Global Limited工作，最近担任鉴证经理。Trojanowski先生在普罗维登斯学院获得会计学学士学位，在普罗维登斯学院获得会计学工商管理硕士学位，是一名注册会计师。
Justin Trojanowski has served as the Company's Corporate Controller, Treasurer and Principal Accounting Officer since September 2022. Previously, Mr. Trojanowski has served as Director, Finance and Assistant Controller from June 2022 through September 2022. Prior to joining the Company, Mr. Trojanowski served as Associate Director, Accounting at Nektar Therapeutics, a biopharmaceutical company, from June 2019 to June 2022. Prior to Nektar, Mr. Trojanowski served as Senior Manager, Accounting at Immune Design, a late stage oncology company that was acquired by Merck in 2019, from June 2018 to May 2019. Prior to Immune Design, Mr. Trojanowski worked at Ernst & Young, Global Limited, a multinational audit and professional services company, from September 2012 to May 2018, most recently as an Assurance Manager. Mr. Trojanowski received his B.S. in Accountancy from Providence College and an M.B.A. in Accountancy from Providence College, and is a Certified Public Accountant.- Justin Trojanowski自2022年9月起担任公司公司财务总监、财务主管和首席会计官。此前，Trojanowski先生于2022年6月至2022年9月期间担任董事、财务和助理财务总监。在加入公司之前，Trojanowski先生于2019年6月至2022年6月期间在生物制药公司内克塔治疗担任副董事，会计部。在加入Nektar之前，Trojanowski先生曾于2018年6月至2019年5月担任高级经理，在Immune Design担任会计，该公司是一家晚期肿瘤公司，于2019年被默沙东收购。在加入Immune Design之前，Trojanowski先生于2012年9月至2018年5月在跨国审计和专业服务公司Ernst & Young，Global Limited工作，最近担任鉴证经理。Trojanowski先生在普罗维登斯学院获得会计学学士学位，在普罗维登斯学院获得会计学工商管理硕士学位，是一名注册会计师。
- Justin Trojanowski has served as the Company's Corporate Controller, Treasurer and Principal Accounting Officer since September 2022. Previously, Mr. Trojanowski has served as Director, Finance and Assistant Controller from June 2022 through September 2022. Prior to joining the Company, Mr. Trojanowski served as Associate Director, Accounting at Nektar Therapeutics, a biopharmaceutical company, from June 2019 to June 2022. Prior to Nektar, Mr. Trojanowski served as Senior Manager, Accounting at Immune Design, a late stage oncology company that was acquired by Merck in 2019, from June 2018 to May 2019. Prior to Immune Design, Mr. Trojanowski worked at Ernst & Young, Global Limited, a multinational audit and professional services company, from September 2012 to May 2018, most recently as an Assurance Manager. Mr. Trojanowski received his B.S. in Accountancy from Providence College and an M.B.A. in Accountancy from Providence College, and is a Certified Public Accountant.